Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Calquence Demonstrates Fewer Incidences of Atrial Fibrillation vs Ibrutinib in Patients with Leukaemia

americanpharmaceuticalreviewJune 09, 2021

Tag: Calquence , AstraZeneca , Ibrutinib , leukaemia

PharmaSources Customer Service